Roche enters the SERD market with FDA approval in late-stage breast cancer
Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second one came first. The drug was
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.